

<b>Policy Name:</b> Guidelines for Availability of Data Sets	<b>Policy Number:</b> 15.1
<b>Section:</b> Data Sharing – 15	<b>Date Revised:</b> December 16, 2024

## 15 Data sharing

Each Alliance study has a formal protocol document, which includes a statement of the objectives of the study. Patient consent and authorization are obtained to collect the individual patient data required for addressing the study objectives. These data are transmitted from the treating or enrolling institution to the Alliance Statistics and Data Management Center (SDMC), where these data are reviewed, processed and stored in the Alliance database. Not all information submitted becomes part of the electronic database; for example, only some information on supporting documents such as operative and pathology reports may be entered into the database. The electronic database is used as the basis for analyses of Alliance studies, with the analyses performed by the staff at the Alliance SDMC.

The procedures described here do not cover requests – from the National Cancer Institute (NCI), the Food and Drug Administration (FDA), or other federal agencies – for information required by federal regulations or by the terms of the grant awards from federal agencies (e.g., Cancer Therapy Evaluation Program (CTEP), Division of Cancer Prevention (DCP) and Division of Cancer Control and Population Sciences (DCCPS), NCI, and National Institutes of Health (NIH) to the Alliance. Such requests will be honored as expeditiously as possible.

For Data and Safety Monitoring Board (DSMB) monitored studies, see section 16 for more information on restrictions for data release.

This policy covers requests for existing data, not requests for collection of additional data. Requests for individual-level genomic or other large-scale genomic data not used in the primary publication (see section 15.2) may be subject to other NCI and NIH regulations.

Data requested by an investigator can include images and/or data generated from Alliance laboratory correlative studies. However, requests for use of biospecimens are covered by a separate evaluation and review procedure described in section 11.

The sharing of data with industry is further described in section 13. However, in cases where industry requests data from studies in which it has not participated, it would follow the procedure indicated in this section.

### 15.1 Clinical Trial datasets

#### 15.1.1 Clinical dataset definition

A clinical data set refers to individual-level de-identified data sets that would be sufficient to reproduce results provided in a publication (i.e., published manuscript) containing the primary study analysis.

<b>Policy Name:</b> Guidelines for Availability of Data Sets	<b>Policy Number:</b> 15.1
<b>Section:</b> Data Sharing – 15	<b>Date Revised:</b> December 16, 2024

### 15.1.2 Guidelines for availability of data sets

For phase II/III and III studies primary publications published on or after January 1, 2015, it is anticipated that clinical data sets will be available via the NCTN/NCORP Data Archive. It is anticipated that data sets containing patient-level entry data of all variables summarized in the primary publication(s) will be available within 6 months after the earliest publication date of the primary analysis. In addition, all data from secondary publications of these phase II/III and phase III trials that contain updated survival data published on or after April 01, 2018 will be available within 6 months of the earliest publication date. Clinical data from secondary publications of phase II/III and phase III trials that include large-scale genomic data consisting of 50 or more variables on 50 or more patients (e.g., DNA or RNA sequencing, gene expression microarray, proteomics, methylomics, etc.) may be requested by NCI for submission to the NCTN/NCORP Data Archive. Data from all other publications (e.g., quality-of-life, economic, toxicity data, biomarker data or meta-analyses, phase II primary, etc.) may be submitted to the Archive on a voluntary basis.

The NCTN/NCORP Data Archive has its own requesting procedures: <https://nctn-data-archive.nci.nih.gov>. Some data may also be available via Project Data Sphere: <https://www.projectdatasphere.org/projectdatasphere/html/home>. If the desired data are not contained within the NCTN Data Archive or Project Data Sphere, these data will be available to individuals via the requesting procedures described in section 15.3 (subject to restrictions in sections 15.4 and 15.5). This process could take several months depending on workload and prioritization within the SDMC.

For non-phase III studies, clinical data sets containing the variables analyzed in the primary results paper will be available upon request (subject to restrictions in sections 15.4 and 15.5). This process could take several months, based on the type of request and workload amount/priorities of the SDMC. The release of data may also be constrained in cases where the sample sizes are too small to reliably identify data

Release of data collected in a clinical trial conducted under a binding collaborative agreement between CTEP and a pharmaceutical/biotechnology company must be in compliance with the terms of the binding collaborative agreement and must be approved by CTEP and the company. Release of data is also subject to the terms of any contracts between the Alliance and other entities, which cover any of the requested data. These two considerations could, in some instances, delay the release of data to requesting investigators.

<b>Policy Name:</b> Large-scale Genomic Data Sharing	<b>Policy Number:</b> 15.2
<b>Section:</b> Data Sharing – 15	<b>Date Revised:</b> December 16, 2024

## **15.2 Large-scale genomic data sharing**

### **15.2.1 Large-scale genomic data definition**

Large-scale genomic data refers to a dataset where the number of features on the assay is far greater than the number of samples tested in the study. Further details can be found in the NIH definition of large-scale genomic data ([https://osp.od.nih.gov/wp-content/uploads/Supplemental\\_Info\\_GDS\\_Policy.pdf](https://osp.od.nih.gov/wp-content/uploads/Supplemental_Info_GDS_Policy.pdf)).

### **15.2.2 Guidelines for availability of data sets**

Generally, large-scale genomic data will be available publically within 6 months of publication. Refer to chapter 11 for more details

### **15.2.3 NIH data sharing policies**

Assay types used most often include microarrays and next generation sequencing. In accordance with NIH data sharing policies, large-scale genomic data generated from Alliance studies are deposited into the database on Genotypes and Phenotypes (dbGaP) or other appropriate public data repository. The study team statisticians and bioinformaticists, commonly but not always within the Alliance SDMC Computational Genomics and Bioinformatics (CGB) Unit, are responsible for this process. It is expected that the corresponding large-scale genomic data sharing policies will, of necessity, evolve as NIH policies regarding large-scale data evolve.

### **15.2.4 Alliance large-scale genomic studies**

Alliance large-scale genomic studies are typically conducted as substudies to Alliance clinical trials including large-scale genomic data and phenotype data (clinical patient data, i.e., demographics, outcome(s), adverse events).

Phenotype data prepared by SDMC and the study team associated with analyses of large-scale genomic data will determine when the standard quality control processes have been completed and prepare data for applicable submission(s).

De-identified (coded) high throughput genotype data and other large-scale genomic data (which may include primary analysis files and/or intermediate files) will be made available to public repositories (such as dbGaP) according to NIH policies.

The study analysis team is responsible for data deposits/sharing; the Alliance SDMC CGB Unit is not responsible for data deposits/sharing in situations in which they are not members of the study analysis team.

<b>Policy Name:</b> Large-scale Genomic Data Sharing	<b>Policy Number:</b> 15.2
<b>Section:</b> Data Sharing – 15	<b>Date Revised:</b> December 16, 2024

If the desired data are not contained within a public repository, large-scale genomic data will be available to individuals via the requesting procedures described in section 15.3 (subject to restrictions in sections 15.4 and 15.5). This process could take several months depending on workload and prioritization within the SDMC and/or Translational Research Program (Alliance Standardized Translational Omics Resource, A-STOR), which houses Alliance large-scale genomic data for sharing 11.12).

<b>Policy Name:</b> Request Procedures	<b>Policy Number:</b> 15.3
<b>Section:</b> Data Sharing – 15	<b>Date Revised:</b> December 16, 2024

### 15.3 Request procedures

The Alliance makes research data available to investigators, as required by NIH policies. Any investigator who wishes to use individual patient data from one or more of the Alliance studies that are not available through NCTN/NCORP Data Archive, Project Data Sphere, or large-scale genomic repositories (i.e., dbGAP) must make a formal request to the Alliance Data Sharing Working Group.

The Alliance requires the investigator to fill out a formal request form, available on the Alliance website. The Alliance also requires the investigator to sign a data release specifying who will have access to the individual patient data and specifying that it will not be shared with others outside this specified set of individuals unless first approved by the Alliance.

There will be no scientific review of requests for data; principles regarding requests for data housed in the Alliance TRP A-STOR large scale genomic data repository are in Chapter 11. If the Alliance is unable to fulfill a request, the Alliance will inform the investigator(s) of the reason the request cannot be fulfilled. In most cases it is likely the investigator(s) will be able to amend the request to comply with the procedures. If the Alliance believes the request will not be amendable, the Alliance will inform the investigator of the appeals process outlined in section 15.6, and also notify the lead chief of the Clinical Investigations Branch (CIB) of CTEP in the Division of Cancer Treatment and Diagnosis (DCTD) at the NCI, the lead NCTN program director, and the DCP or NCORP Director, as appropriate. Release of data is subject to the disclaimer in section 15.5.

<b>Policy Name:</b> Regulatory Considerations	<b>Policy Number:</b> 15.4
<b>Section:</b> Data Sharing – 15	<b>Date Revised:</b> December 16, 2024

## 15.4 Regulatory considerations

All research use of data collected on human subjects from network group studies led by the Alliance Central Protocol Operations Program and Alliance SDMC is subject to applicable Office of Human Research Protections (OHRP) regulations and to applicable regulations of the Privacy Rule of the Health Insurance Portability and Accountability Act (HIPAA). Generally, patients consent to have their data stored and possibly shared for the purpose of future research, with protections for privacy. The standard policy is to provide data that have been rendered fully anonymous, de-identified, or coded. IRB approval from an investigator’s institution may be required to fulfill requests for non-de-identified data.

Guidance on these matters can be found in the OHRP document “Guidance on Research Involving Coded Private Information or Biological Specimens” located at <http://www.hhs.gov/ohrp/policy/cdebiol.html>. Information is also available on the NIH website ([http://privacyruleandresearch.nih.gov/clin\\_research.asp](http://privacyruleandresearch.nih.gov/clin_research.asp)) for Clinical Research and the HIPAA Privacy Rule. The criteria for de-identification of data under HIPAA are given in the Code of Federal Regulations, Part 46, Section 164.514. It is possible to conduct most projects using coded data (as described in the OHRP Guidance) that meet the criteria for a limited data set that can be released under a data use agreement (as described in Part 46 of the CFR, Section 164.512 and in the NIH HIPAA guidance documents), without obtaining additional patient consent or authorization.

<b>Policy Name:</b> Release Conditions and Disclaimer	<b>Policy Number:</b> 15.5
<b>Section:</b> Data Sharing – 15	<b>Date Revised:</b> December 16, 2024

## 15.5 Release conditions and disclaimer

A simple, formal data release form specifying who will have access to the individual patient data (and specifying that it will not be shared with others outside this specified set of individuals), as well as covering the release conditions described below and the regulatory considerations described in sections 15.3 and 15.4 above, is required.

It is anticipated that most data requests can be provided as non-complex data sets in electronic form.

In releasing data, the Alliance makes no representations and extends no warranties of any kind, either expressed or implied. There are no expressed or implied warranties of merchantability or fitness for a particular purpose, or that the use of data will not infringe any patent, copyright, trademark, or other proprietary rights. No indemnification for any loss, claim, damage, or liability is intended or provided.

Data ownership and authorship guidelines are contained in sections 10.1 and 10.4.3.2.

When abstracts or manuscripts are based on Alliance-led analyses using data shared from multiple studies, authorship will include all members of the research team involved in the current research. The Alliance encourages the inclusion of the original study teams in assignment of abstract or manuscript authorship credits. This applies to Alliance-led meta-analyses of data sets obtained from the Alliance, as well as to meta-analyses of Alliance data sets available through the NCTN Data Archive or Project Data Sphere. Full authorship guidelines and further publications guidelines are contained in section 10.4.3.2.

<b>Policy Name:</b> Appeals Process	<b>Policy Number:</b> 15.6
<b>Section:</b> Data Sharing – 15	<b>Date Revised:</b> December 16, 2024

## **15.6 Appeals process**

If a request for data is denied, the applicant may appeal the decision. The appeal is reviewed by the Alliance Group Chair, the lead NCTN or NCORP Program Director (as applicable), CTEP or DCP Associate Director or his/her designee (as applicable), and an outside statistician (i.e., a statistician who is not a member of the Alliance). The outside statistician is named jointly by the Alliance Group Chair and the lead NCTN or NCORP Program Director.



<b>Policy Name:</b> Fees	<b>Policy Number:</b> 15.7
<b>Section:</b> Data Sharing – 15	<b>Date Revised:</b> December 16, 2024

## 15.7 Fees

Routine costs associated with preparing standard data sets are viewed by NCI as covered by grants for the Alliance Operations Center and Alliance SDMC funded under the NCTN Program, or the Alliance Research Base under the NCORP program. Fees will not be charged for the release of non-complex electronic data sets.

Sometimes the data requested will not all be coded in the Alliance database but will be available from supplementary material that was submitted as part of the trial. In this case, data would need to be abstracted from the supplementary material. Data abstractions can only be performed if adequate funding to support the abstraction is available. Even if funding is available, the Alliance may not have staff available to perform the abstraction. In this situation, Alliance may consider inviting the investigator(s) to the Alliance SDMC to perform the abstraction. Some funding for clerical support may still be required.

For large-scale genomic data requests, sometimes data requested will not have been generated during completion of the original work, and thus would require additional bioinformatic analyses to generate the requested data. In this case, raw files would be shared so that the requestor can generate the needed data at their expense. A fee may be required for sharing large files and/or additional analysis.

Likewise, when data requested require data sets not available in easily obtained electronic format, especially for legacy trials, the Alliance may require funding for support to create the data set in an electronic format. Any fees will be limited to the actual time, effort, and materials required for preparing and documenting the data set.